Retatrutide

Description

Retatrutide (LY3437943) is a novel triple incretin receptor agonist that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-agonist approach represents the cutting edge of metabolic peptide research, engaging three distinct but interconnected hormonal pathways involved in energy homeostasis, glucose regulation, and lipid metabolism. In clinical research, Retatrutide has demonstrated significant effects on body weight, glycemic control, and metabolic parameters. The glucagon receptor agonism component adds a thermogenic and hepatic lipid-reducing dimension not present in dual GLP-1/GIP agonists. Retatrutide is an important research tool for studying the interplay between incretin and glucagon signaling in metabolic regulation. Supplied as a lyophilized powder. For research use only.